Effects of L-DOPA on pharmacological parkinsonism.
D000293:Adolescent; D000328:Adult; D002746:Chlorpromazine / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D005260:Female; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D010919:Placebos; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy
D010919:Placebos; D004295:Dihydroxyphenylalanine; D006220:Haloperidol; D002746:Chlorpromazine